Clinical trials: Recurrent Clostridioides Difficile Infection

Recurrent Clostridioides Difficile Infection

The Clostridioides Difficile Trial of REC-3964

• Terminated
• Age: 18 to 115 years
• Phase 2
• Pill or oral medicine
• Results posted

This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of REC-3964 (doses of either 250 mg or 500 mg PO every 12 hours) for the reduction of Clostridioides difficile…

Trial name

ALDER (NCT06536465)

Testing

REC-3964

Where

2 sites in United States

Volunteers

3 people

Sponsor

Recursion Pharmaceuticals Inc.